Supercharge Your Innovation With Domain-Expert AI Agents!

Anti-tnf antibody compositions, and methods for treatment of psoriatic arthritis

A technology for psoriatic arthritis and psoriasis, applied in chemical instruments and methods, antibodies, drug combinations, etc., can solve the problems of low affinity, cell culture, low-yield, low-affinity, etc.

Pending Publication Date: 2022-01-14
JANSSEN BIOTECH INC
View PDF147 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these and other methods can still result in antibodies or fragments that are somewhat immunogenic, have low affinity, low avidity, or are problematic in cell culture, scale-up, production, and / or low yield
Therefore, such antibodies or fragments may be less suitable for manufacture or use as therapeutic proteins

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-tnf antibody compositions, and methods for treatment of psoriatic arthritis
  • Anti-tnf antibody compositions, and methods for treatment of psoriatic arthritis
  • Anti-tnf antibody compositions, and methods for treatment of psoriatic arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0358] Example 1: Cloning and expression of TNF antibody in mammalian cells .

[0359] A typical mammalian expression vector contains at least one promoter element that mediates transcriptional initiation of the mRNA and antibody coding sequences, as well as signals required for transcriptional termination and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences, and intervening sequences flanked by donor and acceptor sites for RNA splicing. Efficient transcription can be achieved using the following sequences: early and late promoters from SV40, long terminal repeats (LTRS) from retroviruses such as RSV, HTLVI, HIVI, and early Promoter. However, cellular elements (such as the human actin promoter) can also be used. Suitable expression vectors for practicing the invention include, for example, vectors such as pIRES1neo, pRetro-Off, pRetro-On, PLXSN or pLNCX (Clonetech Labs, Palo Alto, CA), pcDNA3.1 (+ / -), pcDNA / Zeo (+ / -) or pcDNA3.1 / Hy...

Embodiment 2

[0368] Example 2: Production of high-affinity human IgG monoclonal antibodies reactive with human TNF using transgenic mice .

[0369] Summarize. Transgenic mice containing human heavy and light chain immunoglobulin genes have been used to generate high-affinity, fully human monoclonal antibodies that can be used therapeutically to inhibit TNF in the treatment of one or more TNF-mediated effect of the disease. (CBA / J x C57 / BL6 / J)F containing human variable and constant region antibody transgenes for heavy and light chains 2 Hybrid mice were immunized with human recombinant TNF (Taylor et al., Intl. Immunol. 6:579-591 (1993); Lonberg et al., Nature 368:856-859 (1994); Neuberger, M., Nature Biotech. 14:826 (1996); Fishwild et al., Nature Biotechnology 14:845-851 (1996)). Several fusions produced one or more panels of fully human TNF-reactive IgG monoclonal antibodies. The fully human anti-TNF antibody was further characterized. All were IgG1κ. Such antibodies were found ...

Embodiment 3

[0390] Example 3: Production of Human IgG Monoclonal Antibodies Reactive to Human TNFα .

[0391] Summarize. (CBA / J x C57BL / 6J)F containing human variable and constant region antibody transgenes of heavy and light chains 2 Hybrid mice (1-4) were immunized with recombinant human TNFα. One fusion, designated GenTNV, produced eight fully human IgG1κ monoclonal antibodies that bind to immobilized recombinant human TNFα. Shortly after identification, the eight cell lines were handed over to the Institute of Molecular Biology for further characterization. Because these Mabs are fully human in sequence, they are expected to be less immunogenic in humans than cA2(Remigram).

[0392] abbreviation. BSA-Bovine Serum Albumin; CO 2 - carbon dioxide; DMSO - dimethyl sulfoxide; EIA - enzyme immunoassay; FBS - fetal bovine serum; H 2 o 2 - hydrogen peroxide; H - heavy chain; HRP - horseradish peroxidase; ID - intradermal; Ig - immunoglobulin; TNF - tissue necrosis factor alpha; IP - ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to compositions and methods utilizing anti-TNF antibodies or antigen binding fragments thereof in a treatment for active Psoriatic Arthritis (PsA), e.g., a treatment utilizing the anti-TNF antibody having a heavy chain (HC) comprising amino acid sequence SEQ ID NO:36 and a light chain (LC) comprising amino acid sequence SEQ ID NO:37.

Description

[0001] Reference Sequence Listing Submitted Electronically [0002] This application contains a Sequence Listing submitted electronically via EFS-Web as an ASCII formatted Sequence Listing with the filename "JBI6103WOPCT1SeqListing.txt", dated May 1, 2020, and 25kb in size. This Sequence Listing submitted via EFS-Web is part of this specification and is hereby incorporated by reference in its entirety. technical field [0003] The present invention relates to compositions and methods for treating active psoriatic arthritis (PsA) using anti-TNF antibodies or antigen-binding fragments thereof, for example, using a heavy chain (HC) comprising the amino acid sequence SEQ ID NO: 36 and comprising amino acid Treatment with an anti-TNF antibody of the light chain (LC) of the sequence SEQ ID NO:37. Background technique [0004] TNFα is a soluble homotrimer of 17kD protein subunits. There is also a membrane bound 26 kD precursor form of TNF. [0005] Cells other than monocytes or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/24A61K39/395A61P37/06
CPCC07K16/241C07K2317/21A61K2039/505A61K39/3955A61K2039/54A61K2039/545A61P37/06A61K2300/00A61P19/02A61K9/0019A61K31/519
Inventor D·D·哈里森E·C·夏L-L·金K·H·罗
Owner JANSSEN BIOTECH INC
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com